We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gene Testing in Patients With Colon Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00003571
First Posted: July 15, 2003
Last Update Posted: July 6, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology
November 1, 1999
July 15, 2003
July 6, 2016
August 1998
January 2006   (Final data collection date for primary outcome measure)
disease free survival [ Time Frame: Up to 10 years ]
Not Provided
Complete list of historical versions of study NCT00003571 on ClinicalTrials.gov Archive Site
  • overall survival [ Time Frame: Up to 10 years ]
  • tumor replication error status [ Time Frame: Up to 10 years ]
  • determine the prognostic and predictive values for response to this therapy [ Time Frame: Up to 10 years ]
Not Provided
Not Provided
Not Provided
 
Gene Testing in Patients With Colon Cancer
Tumor Replication Error (RER) Status and Outcome in a Colon Cancer Adjuvant Chemotherapy Trial

RATIONALE: Analyzing the structure of genes found in a person's cancer cells may help doctors improve methods of treating patients with colon cancer.

PURPOSE: Clinical trial to study the genes of patients treated with chemotherapy for colon cancer.

OBJECTIVES:

  • Determine the relationship between disease free survival, overall survival, and tumor replication error status for patients who have received adjuvant chemotherapy for colon cancer on CALGB protocol 8896.
  • Determine the prognostic and predictive values for response to this therapy in these patients.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Samples of tumor and normal tissue
Non-Probability Sample
Patients previously enrolled on CALGB-8896.
Colorectal Cancer
  • Genetic: mutation analysis
  • Genetic: tumor replication error analysis
Samples of tumor and normal tissue
Samples of tumor and normal tissue are obtained from CALGB 8896 patients. The samples are tested for somatic mutations and tumor replication error (RER) tumor status. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
Interventions:
  • Genetic: mutation analysis
  • Genetic: tumor replication error analysis

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
January 2006
January 2006   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Patients who received chemotherapy for colon cancer as part of CALGB protocol 8896
  • Underwent an initial resection for adenocarcinoma of the colon and were determined to have a high risk of tumor recurrence based upon nodal disease or local extension of tumor with obstruction or perforation due to tumor
  • Surgical specimen blocks available, including tumor tissue and normal tissue
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00003571
CALGB-9865
U10CA031946 ( U.S. NIH Grant/Contract )
CLB-9865
CDR0000066637 ( Registry Identifier: NCI Physician Data Query )
No
Not Provided
Not Provided
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Study Chair: Monica M. Bertagnolli, MD Dana-Farber/Brigham and Women's Cancer Center
Alliance for Clinical Trials in Oncology
July 2016